116 related articles for article (PubMed ID: 25053388)
41. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
[TBL] [Abstract][Full Text] [Related]
42. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
43. Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.
Wright CW; Aikman MS; Werts E; Seabolt J; Haeusler JM
Clin Ther; 2009 Nov; 31(11):2722-34. PubMed ID: 20110014
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin A microemulsion: a randomized, open-label, two-period crossover study in healthy adult male Mexican volunteers.
Piñeyro-López A; Piñeyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez-Silva M; Waksman N; E Salazar-Leal M; Luján-Rangel R
Clin Ther; 2007 Sep; 29(9):2049-54. PubMed ID: 18035203
[TBL] [Abstract][Full Text] [Related]
45. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
Ahmad M; Pervaiz F
Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
[TBL] [Abstract][Full Text] [Related]
46. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Banerji U; Camidge DR; Verheul HM; Agarwal R; Sarker D; Kaye SB; Desar IM; Timmer-Bonte JN; Eckhardt SG; Lewis KD; Brown KH; Cantarini MV; Morris C; George SM; Smith PD; van Herpen CM
Clin Cancer Res; 2010 Mar; 16(5):1613-23. PubMed ID: 20179232
[TBL] [Abstract][Full Text] [Related]
47. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults.
Park K; Kim YS; Kwon KI; Park MS; Lee YJ; Kim KH
Clin Ther; 2007 Jan; 29(1):154-62. PubMed ID: 17379055
[TBL] [Abstract][Full Text] [Related]
48. Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study.
Izquierdo I; Borja J; Rovira S; Pelagio P; Torres F; Cebrecos J; García-Rafanell J
Arzneimittelforschung; 2010; 60(1):36-41. PubMed ID: 20184225
[TBL] [Abstract][Full Text] [Related]
49. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
[TBL] [Abstract][Full Text] [Related]
50. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
[TBL] [Abstract][Full Text] [Related]
51. Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food.
Kaul S; Ji P; Lu M; Nguyen KL; Shangguan T; Grasela D
Am J Health Syst Pharm; 2010 Feb; 67(3):217-22. PubMed ID: 20101064
[TBL] [Abstract][Full Text] [Related]
52. Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Singh R; Mehrotra S; Gopalakrishnan M; Gojo I; Karp JE; Greer JM; Chen A; Piekarz R; Kiesel BF; Gobburu J; Rudek MA; Beumer JH;
Cancer Chemother Pharmacol; 2019 Feb; 83(2):319-328. PubMed ID: 30456480
[TBL] [Abstract][Full Text] [Related]
53. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies.
Salem AH; Giranda VL; Mostafa NM
Clin Pharmacokinet; 2014 May; 53(5):479-88. PubMed ID: 24452810
[TBL] [Abstract][Full Text] [Related]
54. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
Patnaik A; Tolcher A; Beeram M; Nemunaitis J; Weiss GJ; Bhalla K; Agrawal M; Nichols G; Middleton S; Beryozkina A; Sarapa N; Peck R; Zhi J
Cancer Chemother Pharmacol; 2015 Sep; 76(3):587-95. PubMed ID: 26210682
[TBL] [Abstract][Full Text] [Related]
55. Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
Cheeti S; Hou HH; Nelson E; Walker H; Chen B; Morley R; Gates M; Musib L; Girish S; Sahasranaman S; Liu L
Pharm Res; 2018 Oct; 35(12):233. PubMed ID: 30324422
[TBL] [Abstract][Full Text] [Related]
56. Bioavailability of valproic acid under fasting/nonfasting regimens.
Chun AH; Hoffman DJ; Friedmann N; Carrigan PJ
J Clin Pharmacol; 1980 Jan; 20(1):30-6. PubMed ID: 6766956
[TBL] [Abstract][Full Text] [Related]
57. Effect of food on the bioavailability of cyclandelate from commercial capsules.
Kaniwa N; Ogata H; Aoyagi N; Ejima A; Takahashi T; Uezono Y; Imazato Y
Clin Pharmacol Ther; 1991 Jun; 49(6):641-7. PubMed ID: 2060253
[TBL] [Abstract][Full Text] [Related]
58. Effects of food on absorption of mefenamic acid from two commercial capsules differing in bioavailability under the fasting state.
Hamaguchi T; Shinkuma D; Yamanaka Y; Mizuno N
J Pharmacobiodyn; 1987 Jan; 10(1):21-5. PubMed ID: 3585692
[TBL] [Abstract][Full Text] [Related]
59. [Oral bioavailability of oncological preparations: the intake conditions are often decisive].
Weitschies W
Urologe A; 2014 Dec; 53(12):1772-8. PubMed ID: 25391438
[TBL] [Abstract][Full Text] [Related]
60. Poorly specified fasting conditions in clinical research could lead to treatment failure.
Lubberman FJE; Burger D; van Erp NP
Lancet Oncol; 2017 May; 18(5):571-573. PubMed ID: 28495277
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
